All In Biotech

Drug Trial Radar · NCT03227224

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 287 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

287

Actual

Start

Aug 16, 2017

Primary completion

Jan 12, 2019

Study completion Jan 19, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.

Conditions

  • Depressive Disorder, Major

Interventions

  • PlaceboDrug

    Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

  • JNJ-42847922Drug

    Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Week 6
  2. Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and TolerabilityTime frame: Up to Week 8
  3. Percentage of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Up to Week 8
  4. Change From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8Time frame: Baseline and Day 8
  5. Change From Baseline in Vital Signs (SBP and DBP) at Day 22Time frame: Baseline and Day 22
  6. Change From Baseline in Vital Signs (SBP and DBP) at Day 42Time frame: Baseline and Day 42
  7. Change From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)Time frame: Baseline and Endpoint (Week 6)
  8. Change From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8Time frame: Baseline and Day 8
  9. Change From Baseline in Vital Sign (PR) at Day 22Time frame: Baseline and Day 22
  10. Change From Baseline in Vital Sign (PR) at Day 42Time frame: Baseline and Day 42
  11. Change From Baseline in Vital Sign (PR) at Endpoint (Week 6)Time frame: Baseline and Endpoint (Week 6)
  12. Change From Baseline in Vital Sign (Temperature) at Day 8Time frame: Baseline and Day 8
  13. Change From Baseline in Vital Sign (Temperature) at Day 22Time frame: Baseline and Day 22
  14. Change From Baseline in Vital Sign (Temperature) at Day 42Time frame: Baseline and Day 42
  15. Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)Time frame: Baseline and Endpoint (Week 6)
  16. Change From Baseline in Physical Examination (Waist Circumference) at Day 42Time frame: Baseline and Day 42
  17. Change From Baseline in Physical Examination (Body Weight) at Day 42Time frame: Baseline and Day 42
  18. Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42Time frame: Baseline and Day 42
  19. Percentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined LimitsTime frame: Up to Week 6
  20. Percentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 8
  21. Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42Time frame: Baseline and Day 42
  22. Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43Time frame: Day 43
  23. Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56Time frame: Day 49 to Day 56

Locations

101 sites in 8 countries. Site status is shown where the registry gives one.

  • California Pharmaceutical Research Institute, Inc.

    Anaheim, California

  • Catalina Research Institute

    Chino, California

  • Synergy Clinical Research Center Of Escondido

    Lemon Grove, California

  • Asclepes Research

    Panorama City, California

  • Sharp Mesa Vista Hospital

    San Diego, California

  • SF-Care, Inc

    San Rafael, California

  • Collaborative NeuroScience Network

    Torrance, California

  • Elite Clinical Trials

    Wildomar, California

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida

  • Clinical NeuroScience Solutions Inc

    Jacksonville, Florida

  • Innovative Clinical Research Inc

    Lauderhill, Florida

  • Qps-Mra, Llc

    Miami, Florida

  • Galiz Research

    Miami Springs, Florida

  • Behavioral Clinical Research , Inc

    North Miami, Florida

  • Clinical NeuroScience Solutions Inc

    Orlando, Florida

  • Compass Research LLC

    Orlando, Florida

  • Emory University

    Atlanta, Georgia

  • Radiant Research, Inc.

    Atlanta, Georgia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • NeuroTrials Research, Inc.

    Atlanta, Georgia

  • Chicago Research Center

    Chicago, Illinois

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Joliet Center for Clinical Research

    Joliet, Illinois

  • Clinilabs

    New York, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Clinical Trials of America

    Winston-Salem, North Carolina

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Neuro Behavioral Clinical Research

    Canton, Ohio

  • Midwest Clinical Research Center

    Dayton, Ohio

  • Suburban Research Associates

    Media, Pennsylvania

  • Family Psychiatry of The Woodlands

    The Woodlands, Texas

  • Core Clinical Research

    Everett, Washington

  • Mental Health Center Prof. Dr. Ivan Temkov

    Burgas, Bulgaria

  • State Psychiatric Hospital Kardzhali

    Kardzhali, Bulgaria

  • State Psychiatric Hospital - Lovech

    Lovech, Bulgaria

  • UMHAT 'Dr. Georgi Stranski', EAD

    Pleven, Bulgaria

  • MC 'Hipokrat - N', EOOD

    Plovdiv, Bulgaria

  • Mental Health Center - Rousse

    Rousse, Bulgaria

  • MHC - Sofia, EOOD

    Sofia, Bulgaria

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.